{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:44:19Z","timestamp":1787064259996,"version":"build-2736575974"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to investigate the prevalence of autoimmune polyendocrine syndromes in patients with SLE and to assess whether autoimmune polyendocrine syndromes predict higher disease activity or worse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical charts of 417 SLE patients (meeting SLICC 2012 and\/or EULAR\/ACR 2019 criteria)( referred to our centre between 2021 and 2023 were analysed. Autoimmune polyendocrine syndrome cases were identified using ORPHA definitions; 185 autoimmune polyendocrine syndrome\u2013free SLE patients, randomly enrolled, served as controls. Demographic, clinical and serological data were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-seven of 417 (11%) SLE patients had another autoimmune disease affecting the glands that allowed the diagnosis of autoimmune polyendocrine syndrome: 39 were diagnosed with Hashimoto thyroiditis, 6 with Graves\u2019 disease, and 3 with type 1 diabetes mellitus. Forty-five were affected by autoimmune polyendocrine syndrome type 3, and 2 by autoimmune polyendocrine syndrome type 4; no patients were diagnosed with autoimmune polyendocrine syndrome types 1 or 2. A comparison between the autoimmune polyendocrine syndrome\u2013positive and \u2013negative patients revealed no significant differences in clinical or serological features. At the last evaluation, \u223c80% of both groups of patients were in clinical remission, and approximately half of the patients remained on steroid therapy. Autoimmune polyendocrine syndrome\u2013positive patients had a slightly higher median SLICC Damage Index (SDI), although this was not associated with increased disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of autoimmune polyendocrine syndrome among SLE patients is significantly higher than in the general population (11% vs 0.005%), confirming the association between autoimmune thyroiditis and SLE. However, autoimmune polyendocrine syndrome\u2013positive patients do not appear to have a more aggressive disease or develop more complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf320","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:41:19Z","timestamp":1749541279000},"page":"5656-5664","source":"Crossref","is-referenced-by-count":1,"title":["A case\u2013control study on autoimmune polyendocrine syndromes in patients with systemic lupus erythematosus"],"prefix":"10.1093","volume":"64","author":[{"given":"Elda","family":"Piovani","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia Ingrid","family":"Gozzoli","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Ebe Lucia","family":"Della Pina","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barison","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Orlandi","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gatta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]},{"name":"Endocrinology and Metabolism Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Tomasi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Fredi","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]},{"name":"Endocrinology and Metabolism Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Franceschini","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia , Brescia,","place":["Italy"]},{"name":"Department of Clinical and Experimental Sciences, University of Brescia , Brescia,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025110820492735600_keaf320-B1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","article-title":"EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics","volume":"67","author":"Bertsias","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025110820492735600_keaf320-B2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.autrev.2004.07.003","article-title":"Mortality studies in SLE: how far can we improve survival of patients with SLE","volume":"3","author":"Abu-Shakra","year":"2004","journal-title":"Autoimmun Rev"},{"key":"2025110820492735600_keaf320-B3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1191\/096120301701548409","article-title":"European Working Party on Systemic Lupus Erythematosus. European working party on systemic lupus erythematosus: a 10 year report","volume":"10","year":"2001","journal-title":"Lupus"},{"key":"2025110820492735600_keaf320-B4","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1002\/art.11296","article-title":"Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study","volume":"48","author":"Bruce","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2025110820492735600_keaf320-B5","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature Coronary-Artery Atherosclerosis in Systemic Lupus Erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N Engl J Med"},{"key":"2025110820492735600_keaf320-B6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/rheumatology\/keh581","article-title":"Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome","volume":"44","author":"Jim\u00e9nez","year":"2005","journal-title":"Rheumatology"},{"key":"2025110820492735600_keaf320-B7","first-page":"713","article-title":"Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a swedish population based study 1964\u201395","volume":"31","author":"Bj\u00f6rn\u00e5dal","year":"2004","journal-title":"J Rheumatol"},{"key":"2025110820492735600_keaf320-B8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.59.2.110","article-title":"Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls","volume":"59","author":"Gilboe","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2025110820492735600_keaf320-B9","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025110820492735600_keaf320-B10","first-page":"791","article-title":"Review of major endocrine abnormalities in patients with systemic lupus erythematosus","volume":"37","author":"Mu\u00f1oz","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025110820492735600_keaf320-B11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5114\/reum\/170266","article-title":"Autoimmune polyendocrine syndromes associated with autoimmune rheumatic diseases","volume":"61","author":"Jankowska","year":"2023","journal-title":"Rheumatology"},{"key":"2025110820492735600_keaf320-B12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fendo.2017.00138","article-title":"Systemic lupus erythematosus and thyroid autoimmunity","volume":"8","author":"Ferrari","year":"2017","journal-title":"Front Endocrinol"},{"key":"2025110820492735600_keaf320-B13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2249.2004.02561.x","article-title":"Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?","volume":"137","author":"Betterle","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"2025110820492735600_keaf320-B14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4239\/wjd.v6.i1.67","article-title":"Type 1 diabetes and polyglandular autoimmune syndrome: a review","volume":"6","author":"Hansen","year":"2015","journal-title":"World J Diabetes"},{"key":"2025110820492735600_keaf320-B15","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025110820492735600_keaf320-B16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025110820492735600_keaf320-B17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2014.01.007","article-title":"Hashimoto thyroiditis: clinical and diagnostic criteria","volume":"13","author":"Caturegli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025110820492735600_keaf320-B18","first-page":"177","article-title":"Current diagnosis and management of Graves\u2019 disease","volume":"50","author":"Subekti","year":"2018","journal-title":"Acta Med Indones"},{"key":"2025110820492735600_keaf320-B19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1258\/acb.2009.009101","article-title":"The diagnosis and investigation of adrenal insufficiency in adults","volume":"46","author":"Wallace","year":"2009","journal-title":"Ann Clin Biochem Int J Lab Med"},{"key":"2025110820492735600_keaf320-B20","doi-asserted-by":"crossref","first-page":"e88782","DOI":"10.1172\/jci.insight.88782","article-title":"Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"1","author":"Ferre","year":"2016","journal-title":"JCI Insight"},{"key":"2025110820492735600_keaf320-B21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2014.01.044","article-title":"Diagnosis and classification of autoimmune parathyroid disease","volume":"13","author":"Betterle","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025110820492735600_keaf320-B22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.semarthrit.2013.05.003","article-title":"The Systemic Lupus International Collaborating Clinics (SLICC) damage index: a systematic literature review","volume":"43","author":"Sutton","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2025110820492735600_keaf320-B23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0961203309346505","article-title":"SLEDAI-2K for a 30-day window","volume":"19","author":"Touma","year":"2010","journal-title":"Lupus"},{"key":"2025110820492735600_keaf320-B24","doi-asserted-by":"crossref","first-page":"103428","DOI":"10.1016\/j.autrev.2023.103428","article-title":"What is the best instrument to measure disease activity in SLE? \u2013 SLE-DAS vs Easy BILAG","volume":"23","author":"In\u00eas","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2025110820492735600_keaf320-B25","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025110820492735600_keaf320-B26","doi-asserted-by":"crossref","first-page":"899372","DOI":"10.3389\/fimmu.2022.899372","article-title":"Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes","volume":"13","author":"Frazzei","year":"2022","journal-title":"Front Immunol"},{"key":"2025110820492735600_keaf320-B27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1741-7015-7-12","article-title":"Sex differences in rheumatoid arthritis: more than meets the eye","volume":"7","author":"Van Vollenhoven","year":"2009","journal-title":"BMC Med"},{"key":"2025110820492735600_keaf320-B28","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"key":"2025110820492735600_keaf320-B29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.semnephrol.2010.01.007","article-title":"Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis","volume":"30","author":"Ramos","year":"2010","journal-title":"Semin Nephrol"},{"key":"2025110820492735600_keaf320-B30","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.2337\/db14-1497","article-title":"Role of type 1 diabetes\u2013associated SNPs on risk of autoantibody positivity in the TEDDY study","volume":"64","author":"T\u00f6rn","year":"2015","journal-title":"Diabetes"},{"key":"2025110820492735600_keaf320-B31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41586-020-2436-0","article-title":"FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease","volume":"584","author":"Saevarsdottir","year":"2020","journal-title":"Nature"},{"key":"2025110820492735600_keaf320-B32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa073003","article-title":"STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus","volume":"357","author":"Remmers","year":"2007","journal-title":"N Engl J Med"},{"key":"2025110820492735600_keaf320-B33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/ard.2004.022053","article-title":"Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study","volume":"64","author":"Stolt","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025110820492735600_keaf320-B34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ebiom.2019.03.063","article-title":"Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients","volume":"42","author":"James","year":"2019","journal-title":"EBioMedicine"},{"key":"2025110820492735600_keaf320-B35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fimmu.2014.00143","article-title":"Neuro-endocrine networks controlling immune system in health and disease","volume":"5","author":"Procaccini","year":"2014","journal-title":"Front Immunol"},{"key":"2025110820492735600_keaf320-B36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/BOR.0000000000000505","article-title":"Autoimmune manifestations of infections","volume":"30","author":"Jara","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2025110820492735600_keaf320-B37","doi-asserted-by":"crossref","first-page":"103135","DOI":"10.1016\/j.autrev.2022.103135","article-title":"Autoimmune polyendocrine syndrome type 1: clinical manifestations, pathogenetic features, and management approach","volume":"21","author":"Bj\u00f8rklund","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025110820492735600_keaf320-B38","author":"Aamer S, Akram S, Butt MA, Shah A. Co-occurrence of systemic lupus erythematosus and autoimmune polyendocrine syndrome II: is there a pathologic link? Cureus 2020;12:e11187."},{"key":"2025110820492735600_keaf320-B39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1191\/096120301678646209","article-title":"Systemic lupus erythematosus with polyglandular autoimmune syndrome type II: report of an unusual case","volume":"10","author":"Al-Mutairy","year":"2001","journal-title":"Lupus"},{"key":"2025110820492735600_keaf320-B40","doi-asserted-by":"crossref","first-page":"1236878","DOI":"10.3389\/fendo.2023.1236878","article-title":"Autoimmune polyglandular syndrome type 4: experience from a single reference center","volume":"14","author":"Gatta","year":"2023","journal-title":"Front Endocrinol"},{"key":"2025110820492735600_keaf320-B41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/ard.59.3.230","article-title":"Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus","volume":"59","author":"McDonagh","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2025110820492735600_keaf320-B42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1756-185X.13089","article-title":"Hashimoto thyroiditis, anti-thyroid antibodies and systemic lupus erythematosus","volume":"21","author":"Posselt","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2025110820492735600_keaf320-B43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.61.1.70","article-title":"Autoimmune thyroid disease in systemic lupus erythematosus","volume":"61","author":"Pyne","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2025110820492735600_keaf320-B44","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s10067-007-0602-5","article-title":"Thyroid dysfunction in patients with systemic lupus erythematosus (SLE): relation to disease activity","volume":"26","author":"Mader","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2025110820492735600_keaf320-B45","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/rheumatology\/kez562","article-title":"Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry","volume":"59","author":"Mena-V\u00e1zquez","year":"2020","journal-title":"Rheumatology"},{"key":"2025110820492735600_keaf320-B46","article-title":"Decreased prevalence of autoimmune connective tissue diseases in type 1 and type 2 diabetes","volume":"11","author":"Abugharbyeh","year":"2023","journal-title":"Transl Univ Toledo J Med Sci"},{"key":"2025110820492735600_keaf320-B47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40618-017-0740-9","article-title":"Polyglandular autoimmune syndromes","volume":"41","author":"Kahaly","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"2025110820492735600_keaf320-B48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2025110820492735600_keaf320-B49","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1089\/jir.2011.0029","article-title":"The dysregulation of cytokine networks in systemic lupus erythematosus","volume":"31","author":"Apostolidis","year":"2011","journal-title":"J Interferon Cytokine Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf320\/63465475\/keaf320.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5656\/63465475\/keaf320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/11\/5656\/63465475\/keaf320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:49:36Z","timestamp":1762652976000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/11\/5656\/8160082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf320","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,10]]}}}